518-34-3

Tetrandrine, isolated from the root of Stephania tetrandra S Moore, a bis-benzylisoquinoline alkaloid, is a calcium channel blocker. Recently it has been discovered that pronounced drug-dependence and related toxic effects occur in both dogs and rhesus monkeys with this alkaloid on intravenous injection with a dose of 10-150 mg/kg. Tetrandrine is used for the treatment of hypertension, angina, termination of paroxysmal supraventricular tachycardia, pulmonary fibrosis, and other diseases in clinical application, and it also has strong antitumor effects.  Tetrandrine was also approved for lowering blood glucose and free radical damage; its treatment effect on silicosis is significant and superior to conventional immunosuppressive and cytotoxic drugs. Tetrandrine is used in China to treat high blood pressure. Its other pharmacological effects are to be explored in further study.

Indications

Tetrandrine has analgesic, anti-inflammatory, and anti-allergic effects and has a wide range of usage on the cardiovascular system owing to its antihypertensive, anti-myocardial ischemia/reperfusion injury and antiarrhythmic effects. Tetrandrine is a calcium channel protein inhibitor. Tetrandrine blocks the L-type (IC50= 0.3-8 µM) and T-type (IC50= 2.5-20 µM) calcium channels. This product is included in national standards for chemical drugs (Volume 14), British Pharmacopoeia (2017), and European Pharmacopoeia (9.0th ed.). 

InChI:InChI=1/C38H42N2O6/c1-39-15-13-25-20-32(42-4)34-22-28(25)29(39)17-23-7-10-27(11-8-23)45-33-19-24(9-12-31(33)41-3)18-30-36-26(14-16-40(30)2)21-35(43-5)37(44-6)38(36)46-34/h7-12,19-22,29-30H,13-18H2,1-6H3/t29?,30-/m0/s1